Literature DB >> 8656676

Long-term survival and proliferation of precursor-B acute lymphoblastic leukemia cells on human bone marrow stroma.

K Bradstock1, A Bianchi, V Makrynikola, R Filshie, D Gottlieb.   

Abstract

Leukemic cells frequently persist in the bone marrow of patients treated for acute lymphoblastic leukemia (ALL), and may regrow to produce relapse. We have used a long-term co-culture system to analyze the interaction of ALL blasts with components of the marrow microenvironment. Blast cells from 10 cases of precursor-B ALL were cultured on allogeneic human bone marrow stromal layers at 37 degrees C in microtiter wells, and replated when stroma showed evidence of deterioration. Leukemic cells from seven of 10 cases showed evidence of survival and proliferation beyond 30 days in culture, while in three cases there was a progressive decline in the number of viable leukemic cells by 7-21 days. Two cases continued to proliferate for 149 to 332+ days, while five underwent senescence after 34-52 days. In the two cases with long-term proliferation, the leukemic identity of the cells was confirmed by immunophenotyping, cytogenetics, and demonstration of clonal immunoglobulin gene rearrangements. Evidence of selection of leukemic subclones was seen in two cases, with immumophenotypic evidence of loss of CD10 and CD34 antigens, and acquisition of CD20 and surface mu chain. The leukemic cells in these cases grew either in clumps attached to the surface of the stroma, or as'cobblestone areas' beneath the stromal cells. Survival and growth of two evaluable cases was dependent on the continuing presence of stromal cells in the culture system. In one case, direct contact with stroma was shown to be necessary to main- tain viability, while blast cells from the other case survived equally well when separated from the stroma by a 0.4-micron pore size microporous membrane. These results indicate that leu- kemic cells from the majority of cases of precursor-B ALL are able to persist and undergo proliferation in vitro in the presence of normal marrow stroma. This process appears dependent on either direct cell-cell contact, or on diffusible factors derived from the stroma. The availability of ALL cells capable of indefinite proliferation under these conditions will allow further analysis of the mechanisms mediating leukemic cell proliferation.

Entities:  

Mesh:

Year:  1996        PMID: 8656676

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  14 in total

1.  Bone marrow microenvironment modulation of acute lymphoblastic leukemia phenotype.

Authors:  Blake S Moses; William L Slone; Patrick Thomas; Rebecca Evans; Debbie Piktel; Peggi M Angel; Callee M Walsh; Pamela S Cantrell; Stephanie L Rellick; Karen H Martin; James W Simpkins; Laura F Gibson
Journal:  Exp Hematol       Date:  2015-09-25       Impact factor: 3.084

Review 2.  A primitive cell origin for B-cell precursor ALL?

Authors:  C V Cox; A Blair
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

3.  Modeling Chemotherapy Resistant Leukemia In Vitro.

Authors:  William L Slone; Blake S Moses; Rebecca Evans; Debbie Piktel; Karen H Martin; William Petros; Michael Craig; Laura F Gibson
Journal:  J Vis Exp       Date:  2016-02-09       Impact factor: 1.355

4.  Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.

Authors:  E Weisberg; Q Liu; Erik Nelson; A L Kung; A L Christie; R Bronson; M Sattler; T Sanda; Z Zhao; W Hur; C Mitsiades; R Smith; J F Daley; R Stone; I Galinsky; J D Griffin; N Gray
Journal:  Leukemia       Date:  2012-04-03       Impact factor: 11.528

5.  Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase.

Authors:  Shotaro Iwamoto; Keichiro Mihara; James R Downing; Ching-Hon Pui; Dario Campana
Journal:  J Clin Invest       Date:  2007-03-22       Impact factor: 14.808

6.  Long-term in vitro maintenance of clonal abundance and leukaemia-initiating potential in acute lymphoblastic leukaemia.

Authors:  D Pal; H J Blair; A Elder; K Dormon; K J Rennie; D J L Coleman; J Weiland; K S Rankin; A Filby; O Heidenreich; J Vormoor
Journal:  Leukemia       Date:  2016-05-25       Impact factor: 11.528

7.  Modeling The Bone Marrow Microenvironment's Influence on Leukemic Disease.

Authors:  R Evans; K H Martin; B S Moses; W L Slone; I Hare; D Piktel; P Thomas; L F Gibson
Journal:  Transl Biomed       Date:  2015

8.  Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.

Authors:  E Weisberg; A K Azab; P W Manley; A L Kung; A L Christie; R Bronson; I M Ghobrial; J D Griffin
Journal:  Leukemia       Date:  2011-12-20       Impact factor: 11.528

9.  Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist.

Authors:  R Parameswaran; M Yu; M Lim; J Groffen; N Heisterkamp
Journal:  Leukemia       Date:  2011-04-12       Impact factor: 11.528

10.  Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.

Authors:  Ellen Weisberg; Renee D Wright; Douglas W McMillin; Constantine Mitsiades; Arghya Ray; Rosemary Barrett; Sophia Adamia; Richard Stone; Ilene Galinsky; Andrew L Kung; James D Griffin
Journal:  Mol Cancer Ther       Date:  2008-04-29       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.